Skip to content

Study · Randomized controlled trial · n = 80 · 2007

3 results

[Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer].

Botto H, Rouprêt M, Mathieu F, Richard F

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie1 Apr 2007Cited by 8 (Europe PMC)

PMID17489325 (opens in a new tab)DOI10.1016/s1166-7087(07)92270-8 (opens in a new tab)PepBankPUB-17489325
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, 35 triptorelin recipients versus 38 pulpectomy recipients reached the reported testosterone castration threshold at one month.

    In plain wordsIn advanced prostate cancer, 35 triptorelin recipients versus 38 surgery recipients reached the testosterone castration threshold at one month.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedCastration at one month
    Study

    n = 80

    Comparator
    Pulpectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Patients castrated
    35 patients
    triptorelin at one month
    Patients castrated
    38 patients
    pulpectomy at one month

    Source sentences

    Summary
    At 1 month, 38 patients were castrated (plasma testosterone < 0.5 mg/ml) in the pulpectomy group versus 35 in the triptorelin group.
    2 context sentences
    Summary · context
    80 patients with previously untreated locally advanced or metastatic prostate cancer prostate cancer were included in a one-year multicentre, randomized, prospective, open-label therapeutic trial.
    Summary · context
    Patients either received a monthly injection of triptorelin (group 1; n = 40), or were treated by pulpectomy (group 2; n = 40).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, median survival was 37.5 +/- 9 months with triptorelin versus 33 +/- 3 months with pulpectomy.

    In plain wordsIn advanced prostate cancer, median survival was 37.5 months with triptorelin versus 33 months with surgery.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedMedian survival
    Study

    n = 80

    Comparator
    Pulpectomy
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Median survival
    37.5 months
    triptorelin
    Median survival
    33 months
    pulpectomy

    Source sentences

    Summary
    The median survival was 37.5 +/- 9 months in the triptorelin group and 33 +/- 3 months in the pulpectomy group.
    2 context sentences
    Summary · context
    80 patients with previously untreated locally advanced or metastatic prostate cancer prostate cancer were included in a one-year multicentre, randomized, prospective, open-label therapeutic trial.
    Summary · context
    Patients either received a monthly injection of triptorelin (group 1; n = 40), or were treated by pulpectomy (group 2; n = 40).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, specific survival at three years did not differ significantly between triptorelin and pulpectomy.

    In plain wordsIn advanced prostate cancer, specific survival at three years did not differ significantly between triptorelin and surgery.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSpecific survival at three years
    Study

    n = 80

    Comparator
    Pulpectomy
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    At 3 years, no significant difference in specific survival was observed between the 2 groups.
    2 context sentences
    Summary · context
    80 patients with previously untreated locally advanced or metastatic prostate cancer prostate cancer were included in a one-year multicentre, randomized, prospective, open-label therapeutic trial.
    Summary · context
    Patients either received a monthly injection of triptorelin (group 1; n = 40), or were treated by pulpectomy (group 2; n = 40).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.